Back

Medscape, LLC

  • Antineoplastic Agents
  • Ovarian Neoplasms

Beyond Chemotherapy: Integrating Novel Targeted Agents Into Platinum-Resistant Ovarian Cancer Clinical Practice

The goal of this activity is for learners to be better able to individualize treatment plans for patients with platinum-resistant ovarian cancer (PROC) by integrating novel targeted therapies and biomarker-driven strategies.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1.5 creditsNursingUp to 1.5 creditsPharmacyUp to 1.5 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No
Start Date
October 24, 2026
End Date
November 22, 2026

Pricing

Free

Reported to ACCME by the provider

  • Live
  • Credit · Up to 1.5 credits
  • Commercial Support
  • When
    Oct 24 – Nov 21, 2026